[{"id":"ee25e9e3-0db7-4fcb-a64c-11f94e17e205","acronym":"VIWA-1","url":"https://clinicaltrials.gov/study/NCT05099471","created_at":"2021-10-29T14:53:17.774Z","updated_at":"2024-07-02T16:35:04.092Z","phase":"Phase 2","brief_title":"Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT05099471 - VIWA-1","lead_sponsor":"University of Ulm","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" CXCR4 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2024-05-13"},{"id":"3888ab68-3b61-44d8-ac0e-448f59483cfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02677324","created_at":"2021-01-17T17:19:03.491Z","updated_at":"2024-07-02T16:36:10.645Z","phase":"Phase 2","brief_title":"Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia","source_id_and_acronym":"NCT02677324","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • CXCR4","pipe":" | ","alterations":" CXCR4 mutation","tags":["BCL2 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 05/09/2016","start_date":" 05/09/2016","primary_txt":" Primary completion: 02/14/2020","primary_completion_date":" 02/14/2020","study_txt":" Completion: 02/07/2022","study_completion_date":" 02/07/2022","last_update_posted":"2022-05-11"},{"id":"562ebd23-82cd-46f6-9ef4-7d25eaa6ea36","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400437","created_at":"2021-01-18T11:27:12.209Z","updated_at":"2024-07-02T16:36:41.444Z","phase":"Phase 2","brief_title":"Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia","source_id_and_acronym":"NCT02400437","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" MYD88 L265P • CXCR4 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P • CXCR4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ninlaro (ixazomib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2020-09-02"}]